Jiexin Li

Jiexin Li


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2021 in Genome Medicine
Verified
Journal Article
Open access
PDF file
YWYingmin Wu
Yingmin Wu
XYXiangling Yang
Xiangling Yang
GJGuanmin Jiang
Guanmin Jiang
HZHaisheng Zhang
Haisheng Zhang
LGLichen Ge
Lichen Ge
HWHongsheng Wang
Hongsheng Wang
Background: tRNA-derived small RNAs (tDRs), which are widely distributed in human tissues including blood and urine, play an important role in the progression of cancer. However, the expression of tDRs in colorectal cancer (CRC) plasma and their potential diagnostic values have not been systematically explored. Methods: The expression profiles of tDRs in plasma of CRC and health controls (HCs) are investigated by small RNA sequencing. The level and diagnostic value of 5′-tRF-GlyGCC are evaluated by quantitative PCR in plasma samples from 105 CRC patients and 90 HCs. The mechanisms responsible for biogenesis of 5′-tRF-GlyGCC are checked by in vitro and in vivo models. Results: 5′-tRF-GlyGCC is dramatically increased in plasma of CRC patients compared to that of HCs. The area under curve (AUC) for 5′-tRF-GlyGCC in CRC group is 0.882. The combination of carcinoembryonic antigen (CEA) and carbohydrate antigen 199 (CA199) with 5′-tRF-GlyGCC improves the AUC to 0.926. Consistently, the expression levels of 5′-tRF-GlyGCC in CRC cells and xenograft tissues are significantly greater than that in their corresponding controls. Blood cells co-cultured with CRC cells or mice xenografted with CRC tumors show increased levels of 5′-tRF-GlyGCC. In addition, we find that the increased expression of 5′-tRF-GlyGCC is dependent on the upregulation of AlkB homolog 3 (ALKBH3), a tRNA demethylase which can promote tRNA cleaving to generate tDRs. Conclusions: The level of 5′-tRF-GlyGCC in plasma is a promising diagnostic biomarker for CRC diagnosis.

27 April 2023 in Cancer Research
Verified
Journal Article
Closed access
PDF file
HZHaisheng Zhang
Haisheng Zhang
JZJiawang Zhou
Jiawang Zhou
JLJiexin Li
Jiexin Li
ZWZhaotong Wang
Zhaotong Wang
ZCZhuojia Chen
Zhuojia Chen
HWHongsheng Wang
Hongsheng Wang
Angiogenesis is hijacked by cancer to support tumor growth. RNA modifications such as N6-methyladenosine (m6A) can regulate several aspects of cancer, including angiogenesis. Here, we find that m6A triggers angiogenesis in lung cancer by upregulating VEGFA, a central regulator of neovasculature and blood vessel growth. m6A-sequencing and functional studies confirmed that m6A modification of the 5′UTR (untranslated region) of VEGFA positively regulates its translation. Specifically, methylation of a 5′UTR internal ribosome entry site (IRES) recruited the YTHDC2/eIF4GI complex to trigger cap-independent translation initiation. Intriguingly, the m6A methylation site A856 of the 5′UTR was located within the conserved upstream open reading frame (uORF) of VEGFA IRES-A, which overcomes uORF-mediated translation suppression while facilitating G-quadruplex–induced translation of VEGFA. Targeted specific demethylation of VEGFA m6A significantly decreased expression of VEGFA and reduced lung cancer cell–driven angiogenesis. In vivo and clinical data confirmed the positive effects of m6A modification of VEGFA on angiogenesis and tumor growth of lung cancer. This study not only reveals that the m6A/VEGFA axis is a potential target for lung cancer therapy but also expands our understanding of the impact of m6A modification of IRES in the 5′UTR of mRNA on translation regulation. Significance: Methylation of the 5′UTR IRES of VEGFA mRNA increases cap-independent translation via recruitment of the YTHDC2/eIF4GI complex, which stimulates angiogenesis to promote lung tumor growth.

25 January 2020 in Cells
Verified
Journal Article
Open access
PDF file
JLJiexin Li
Jiexin Li
FCFeng Chen
Feng Chen
YPYanxi Peng
Yanxi Peng
ZLZiyan Lv
Ziyan Lv
XLXinyao Lin
Xinyao Lin
HWHongsheng Wang
Hongsheng Wang
N6-methyladenosine (m6A) is the most abundant modification on eukaryotic mRNA, which regulates all steps of the mRNA life cycle. An increasing number of studies have shown that m6A methylation plays essential roles in tumor development. However, the relationship between m6A and the progression of cancers remains to be explored. Here, we reported that transforming growth factor-β (TGFβ1)-induced epithelial–mesenchymal transition (EMT) was inhibited in methyltransferase-like 3 (METTL3) knockdown (Mettl3Mut/−) cells. The expression of TGFβ1 was up-regulated, while self-stimulated expression of TGFβ1 was suppressed in Mettl3Mut/− cells. We further revealed that m6A promoted TGFB1 mRNA decay, but impaired TGFB1 translation progress. Besides this, the autocrine of TGFβ1 was disrupted in Mettl3Mut/− cells via interrupting TGFβ1 dimer formation. Lastly, we found that Snail, which was down-regulated in Mettl3Mut/− cells, was a key factor responding to TGFβ1-induced EMT. Together, our research demonstrated that m6A performed multi-functional roles in TGFβ1 expression and EMT modulation, suggesting the critical roles of m6A in cancer progression regulation.

6 November 2022 in Molecular Oncology
Verified
Journal Article
Open access
ZWZhaotong Wang
Zhaotong Wang
JZJiawang Zhou
Jiawang Zhou
HZHaisheng Zhang
Haisheng Zhang
LGLichen Ge
Lichen Ge
JLJiexin Li
Jiexin Li
HWHongsheng Wang
Hongsheng Wang
N6‐methyladenosine (m6A) is one of the most abundant internal modifications in eukaryotic messenger RNAs (mRNAs) and non‐coding RNAs (ncRNAs). It is a reversible and dynamic RNA modification that has been observed in both internal coding segments and untranslated regions. Studies indicate that m6A modifications play important roles in translation, RNA splicing, export, degradation and ncRNA processing control. In this review, we focus on the profiles and biological functions of RNA m6A methylation on both mRNAs and ncRNAs. The dynamic modification of m6A and its potential roles in cancer development are discussed. Moreover, we discuss the possibility of m6A modifications serving as potential biomarkers for cancer diagnosis and targets for therapy.

21 February 2022 in Advanced Optical Materials
Verified
Journal Article
Closed access
JLJiexin Li
Jiexin Li
ZLZongtao Li
Zongtao Li
JQJiayong Qiu
Jiayong Qiu
JLJiasheng Li
Jiasheng Li

4 October 2024 in Small
Verified
Journal Article
Closed access
ZJZhen Jiang
Zhen Jiang
JLJiexin Li
Jiexin Li
GLGengqi Liu
Gengqi Liu
QQQian Qiu
Qian Qiu
JZJingyu Zhang
Jingyu Zhang
YZYumiao Zhang
Yumiao Zhang